{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:36:31Z","timestamp":1760747791479,"version":"build-2065373602"},"reference-count":6,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.ejca.2021.10.037","type":"journal-article","created":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T16:20:22Z","timestamp":1640017222000},"page":"241-242","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Re: Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers"],"prefix":"10.1016","volume":"162","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3064-737X","authenticated-orcid":false,"given":"Peter","family":"Hersey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2021.10.037_bib1","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ejca.2021.05.005","article-title":"Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers","volume":"153","author":"Schadendorf","year":"2021","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2021.10.037_bib2","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00280-019-03780-y","article-title":"Pharmacokinetic and cytokine profiles of melanoma patients with dabrafenib and trametinib-induced pyrexia","volume":"83","author":"Kim","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"issue":"12","key":"10.1016\/j.ejca.2021.10.037_bib3","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S1470-2045(19)30681-3","article-title":"Shedding light on dabrafenib-induced fevers in patients with melanoma","volume":"20","author":"Hersey","year":"2019","journal-title":"Lancet Oncol"},{"issue":"47","key":"10.1016\/j.ejca.2021.10.037_bib4","doi-asserted-by":"crossref","first-page":"28294","DOI":"10.18632\/oncotarget.25511","article-title":"BRAF inhibitors stimulate inflammasome activation and interleukin 1 beta production in dendritic cells","volume":"9","author":"Hajek","year":"2018","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.ejca.2021.10.037_bib5","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1158\/2159-8290.CD-19-1441","article-title":"Two worlds collide: unraveling the role of the immune system in BRAF-MEK inhibitor responses","volume":"10","author":"Smalley","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2021.10.037_bib6","doi-asserted-by":"crossref","DOI":"10.1111\/pcmr.12870","article-title":"Do innate killing mechanisms activated by inflammasomes have a role in treating melanoma?","author":"Emran","year":"2020","journal-title":"Pigment Cell Melanoma Res"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921012107?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921012107?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:36:10Z","timestamp":1760733370000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804921012107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":6,"alternative-id":["S0959804921012107"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2021.10.037","relation":{},"ISSN":["0959-8049"],"issn-type":[{"type":"print","value":"0959-8049"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Re: Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.10.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.05.005","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}